COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Combined Radiotherapy and Sorafenib in Patients With Hepatoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01319942
Recruitment Status : Unknown
Verified March 2011 by China Medical University Hospital.
Recruitment status was:  Recruiting
First Posted : March 22, 2011
Last Update Posted : March 22, 2011
Information provided by:
China Medical University Hospital

Brief Summary:
This study aims to test the efficacy of combined radiotherapy and sorafenib in patients with locally advanced hepatocellular carcinoma.

Condition or disease Intervention/treatment
Hepatocellular Carcinoma Other: Radiotherapy combined with sorafenib

Detailed Description:

Hepatocellular carcinoma (HCC) is a common cause of cancer mortality in Asia. Most patients present with intermediate or advanced disease. Percutaneous ethanol injection, radiofrequency ablation, and transcatheter arterial chemoembolization (TACE) are not considered as a curative treatment and have achieved very limited success in eradicating large HCC. With the development of new radiotherapy (RT) technique, RT can be more safely given to patients with larger tumor burden. Thus, TACE combined with RT has been suggested for treating large HCC. Based on the results of these studies, RT could achieve a tumor response rate of 50 % to 70 %. However, it has not been definitively shown to prolong the overall or disease-free survival due to lack of a phase III clinical trial. In contrast, a retrospective clinical investigation with molecular study suggests that sublethal dose of RT promoted HCC growth outside RT field.

Two phase III trials were shown to be efficacious and well-tolerated in patients with advanced HCC. Median overall survival was significantly 2 to 3 months longer in the sorafenib group than that in the placebo. It is interesting to recognize the combined therapeutic effect of RT with sorafenib. Based on several preclinical experiments, tumor angiogenesis inhibitors seem to be synergistic with irradiation when using before RT, concurrently with RT, or after RT. Thus, we design a single-arm phase II clinical trial to investigate the efficacy of combined RT with sorafenib.

The eligibility criteria are patients with unresectable HCC; good performance status; no prior radiotherapy for the liver; clinical measurable tumor; good liver function and good compliance. After entering this study, the testee will receive RT to hepatic tumor with concurrently sorafenib with a dose of 400 mg twice daily. Hepatic RT will be performed with a daily fraction size of 2.0 to 2.5 Gy to a total dose of 46 Gy to 60 Gy. After RT, maintenance sorafenib with a dose of 400 mg twice daily will be ongoing. Sorafenib will be continued until the occurrence of clinical or radiologic progression, or the occurrence of either unacceptable adverse events or death. Minimum maintenance duration of 6 months is recommended, but not mandatory. The primary end points are response rate and toxicities profile. The secondary endpoints are time to radiological progression interval (TRPI), overall survival, and quality of life assessment.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 45 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Combined Radiotherapy and Sorafenib in Patients With Hepatoma
Study Start Date : June 2010
Estimated Primary Completion Date : June 2012
Estimated Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer
Drug Information available for: Sorafenib

Group/Cohort Intervention/treatment
Unresectable hepatoma
Unresectable hepatoma, unsuitable for transarterial embolization or local failure after transarterial embolization
Other: Radiotherapy combined with sorafenib
Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
Other Name: Radiotherapy with sorafenib

Primary Outcome Measures :
  1. Response rate [ Time Frame: 1-month and 6-month response rate ]
    1. Response rate at 1-month and 6-month after radiotherapy.
    2. Toxicities profile of combinede treatment

Secondary Outcome Measures :
  1. Time-to radiological progression interval [ Time Frame: 2-years ]
    1. Time-to radiological progression interval
    2. 2-year overall survival
    3. 2-year progression-free survival
    4. Quality of life

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
45 patients withunresectable hepatoma

Inclusion Criteria:

  1. Patients with unresectable hepatoma with transarterial embolization (TAE) failure or who are not suitable for TAE.
  2. Age: 20 ~ 69 years.
  3. ECOG 0 or 1.
  4. Life expectancy of at least 12 weeks.
  5. Child-Pugh A or B (preferentially score ≦ 7).
  6. Cancer of the Liver Italian Program (CLIP) score ≦ 3.
  7. Pretreatment liver function test and renal function test:

    • Total bilirubin < 1.5 times the upper limit of normal (ULN)≦ 3.0(ULN)in patients treated by biliary drainage for obstructive jaundice.
    • GOP/GPT ≦ 5 X of upper limit of normal range.
    • Alkaline phosphatase ≦ 4X of upper limit of normal range.
    • Prothrombin time/partial prothrombin time < 1.5 X of ULN.
    • Serum Creatinine ≦ 1.0 x ULN.
  8. Pretreatment blood count:

    • Hemoglobulin ≧ 9 g/dl.
    • Absolute neutrophil count ≧ 1500/mm3.
    • Platelet count ≧ 100,000/mm3.
  9. Subjects with at least one uni-dimensional or bi-dimensional measurable lesion. Lesion must be measured by CT scan or MRI.
  10. Patients must fully recover from prior therapy that given > 4 weeks before enrolment.11. Signed informed consent must be obtained prior to any study related procedures.

Exclusion Criteria:

  1. Child-Pugh C
  2. CLIP score ≧ 4
  3. Patients with evidence of extrahepatic or metastatic disease
  4. Patients with evidence of massive ascites
  5. Patients receiving previous irradiation to liver
  6. Patients with previous use of Thalidomide less than 6 months from entering of the study
  7. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrythmias requiring anti-arrythmic therapy (beta blockers or digoxin are permitted)
  8. Active clinically serious infections ( > grade 2 CTC version 2)
  9. Patients undergoing renal dialysis
  10. Patients with evidence or history of bleeding diathesis
  11. Prior treatment with EGFR TKIs or VEGFR TKIs
  12. Hypertension uncontrolled by medical therapy
  13. Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper.
  14. Chemotherapy or immunotherapy or other systemic anti-cancer therapy within 4 weeks (6 weeks for nitrosoureas, mitomycin and suramin)
  15. Major surgery within 4 weeks of start of study
  16. Concomitant treatment with strong CYP3A4 inducers or inhibitors
  17. Investigational drug therapy outside of this trial during or within 4 weeks of study entry
  18. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.
  19. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation, including the 30 days period after last study drug dosing.
  20. Pregnant or breast-feeding patients
  21. Known or suspected allergy to the investigational agent or any agent given in association with this trial
  22. Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry
  23. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
  24. Patients with seizure disorder requiring medication
  25. History of organ allograft
  26. Use of biologic response modifiers, such as G-CSF, within 3 week of study entry
  27. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  28. Autologous bone marrow transplant or stem cell rescue within 4 months of study
  29. Patients unable to swallow oral medications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01319942

Layout table for location contacts
Contact: Shang-Wen Chen, MD 886-4-22052121 ext 7450

Layout table for location information
Chi-Mei Hospital Recruiting
Tainan, Taiwan, 600
Contact: Li-Ching Lin, MD    886-6-2812811 ext 53501   
Principal Investigator: Li-Ching Lin, MD         
Taipei Medical University Hospital Recruiting
Taipei, Taiwan, 100
Contact: Jeng-Fong Chiou, MD;PhD    886-2-27372181 ext 2130   
Principal Investigator: Jen-Fong Chiou, MD;PhD         
Sponsors and Collaborators
China Medical University Hospital
Layout table for investigator information
Principal Investigator: Shang-Wen Chen, MD Department of Radiation Oncology, China Medical University Hospital
Layout table for additonal information
Responsible Party: Shang-Wen Chen, China Medical University Hospital Identifier: NCT01319942    
Other Study ID Numbers: RT-sorafenib
First Posted: March 22, 2011    Key Record Dates
Last Update Posted: March 22, 2011
Last Verified: March 2011
Keywords provided by China Medical University Hospital:
Treatment outcome
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action